These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 10355578

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
    Peng B, Tilby MJ, English MW, Price L, Pearson AD, Boddy AV, Newell DR.
    Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
    [Abstract] [Full Text] [Related]

  • 4. Clinical pharmacokinetics and dose optimisation of carboplatin.
    Duffull SB, Robinson BA.
    Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
    Warren K, Gervais A, Aikin A, Egorin M, Balis FM.
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
    [Abstract] [Full Text] [Related]

  • 6. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
    Okamoto H, Nagatomo A, Kunitoh H, Kunikane H, Watanabe K.
    Cancer Chemother Pharmacol; 1998 Sep; 42(4):307-12. PubMed ID: 9744776
    [Abstract] [Full Text] [Related]

  • 7. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
    Bonetti A, Apostoli P, Zaninelli M, Pavanel F, Colombatti M, Cetto GL, Franceschi T, Sperotto L, Leone R.
    Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
    [Abstract] [Full Text] [Related]

  • 8. A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve.
    Ghazal-Aswad S, Calvert AH, Newell DR.
    Cancer Chemother Pharmacol; 1996 Nov; 37(5):429-34. PubMed ID: 8599865
    [Abstract] [Full Text] [Related]

  • 9. Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
    Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E.
    J Clin Oncol; 2023 Oct 01; 41(28):4453-4454. PubMed ID: 37757592
    [Abstract] [Full Text] [Related]

  • 10. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
    Yamamoto R, Kaneuchi M, Nishiya M, Todo Y, Takeda M, Okamoto K, Negishi H, Sakuragi N, Fujimoto S, Hirano T.
    Cancer Chemother Pharmacol; 2002 Aug 01; 50(2):137-42. PubMed ID: 12172979
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer.
    Shimokata T, Ando Y, Yasuda Y, Hamada A, Kawada K, Saito H, Matsuo S, Kondo M, Imaizumi K, Hasegawa Y.
    Cancer Sci; 2010 Dec 01; 101(12):2601-5. PubMed ID: 20860621
    [Abstract] [Full Text] [Related]

  • 14. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support.
    Shen M, Schilder RJ, Obasaju C, Gallo JM.
    Cancer Chemother Pharmacol; 2002 Sep 01; 50(3):243-50. PubMed ID: 12203107
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Phase I evaluation of carboplatin by use of a dosing strategy based on a targeted area under the platinum concentration-versus-time curve and individual glomerular filtration rate in cats with tumors.
    Bailey DB, Rassnick KM, Dykes NL, Pendyala L.
    Am J Vet Res; 2009 Jun 01; 70(6):770-6. PubMed ID: 19496668
    [Abstract] [Full Text] [Related]

  • 17. Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function.
    Duong JK, Veal GJ, Nath CE, Shaw PJ, Errington J, Ladenstein R, Boddy AV.
    Br J Clin Pharmacol; 2019 Jan 01; 85(1):136-146. PubMed ID: 30261554
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel.
    Obasaju CK, Johnson SW, Rogatko A, Kilpatrick D, Brennan JM, Hamilton TC, Ozols RF, O'Dwyer PJ, Gallo JM.
    Clin Cancer Res; 1996 Mar 01; 2(3):549-52. PubMed ID: 9816202
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.